PT2968351T - Formulações de dosagem de modulador de recetores de opioides - Google Patents

Formulações de dosagem de modulador de recetores de opioides

Info

Publication number: PT2968351T
Authority: PT; Portugal
Prior art keywords: opioid receptor; receptor modulator; dosage formulations; modulator dosage; formulations
Prior art date: 2013-03-14

Application number

PT14774006T

Other languages

English (en)

Inventor

Jozef Ceulemans Jens

Costello Tim

Maria Jozef Jans Eugeen

Erna H Heyns Philip

Original Assignee

Allergan Holdings Unlimited Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2014-03-10

Publication date

2018-11-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2968351(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-10 Application filed by Allergan Holdings Unlimited Company filed Critical Allergan Holdings Unlimited Company

2018-11-19 Publication of PT2968351T publication Critical patent/PT2968351T/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PT14774006T 2013-03-14 2014-03-10 Formulações de dosagem de modulador de recetores de opioides PT2968351T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13/829,984 US9675587B2 (en)	2013-03-14	2013-03-14	Opioid receptor modulator dosage formulations

Publications (1)

Publication Number	Publication Date
PT2968351T true PT2968351T (pt)	2018-11-19

Family

ID=51528071

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT14774006T PT2968351T (pt)	2013-03-14	2014-03-10	Formulações de dosagem de modulador de recetores de opioides

Country Status (20)

Country	Link
US (9)	US9675587B2 (pt)
EP (3)	EP2968351B1 (pt)
JP (2)	JP6449225B2 (pt)
KR (1)	KR102435440B1 (pt)
CN (2)	CN110917159A (pt)
AU (1)	AU2014241076B2 (pt)
BR (1)	BR112015022753A8 (pt)
CA (2)	CA3254178A1 (pt)
CY (1)	CY1120892T1 (pt)
DK (1)	DK2968351T3 (pt)
EA (1)	EA031559B1 (pt)
ES (1)	ES2693374T3 (pt)
HU (1)	HUE042748T2 (pt)
IL (2)	IL241561B (pt)
PL (1)	PL2968351T3 (pt)
PT (1)	PT2968351T (pt)
SI (1)	SI2968351T1 (pt)
TR (1)	TR201815953T4 (pt)
TW (1)	TWI648071B (pt)
WO (1)	WO2014159245A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9675587B2 (en)	2013-03-14	2017-06-13	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations
EP3297609A1 (en) *	2015-05-22	2018-03-28	Novartis AG	Pharmaceutical compositions
CN105250232B (zh) *	2015-09-29	2018-08-14	江苏汇智知识产权服务有限公司	一种伊卢多啉肠溶片及其制备方法
EP3515434A4 (en)	2016-09-20	2020-02-26	Sun Pharmaceutical Industries Limited	PROCESSES FOR THE PREPARATION OF ELUXADOLINE
WO2018069770A1 (en) *	2016-10-14	2018-04-19	Allergan Holdings Unlimited Company	Methods of treatment using eluxadoline
US12285411B2 (en) *	2019-09-10	2025-04-29	Aurobindo Pharma Ltd	Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof
CA3166250A1 (en)	2020-02-05	2021-08-12	Gregory G. Plucinski	Drug products for intranasal administration and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US553266A (en)		1896-01-21		Car-fender
US3980766A (en)	1973-08-13	1976-09-14	West Laboratories, Inc.	Orally administered drug composition for therapy in the treatment of narcotic drug addiction
JP2711759B2 (ja)	1990-10-24	1998-02-10	エスエス製薬株式会社	止瀉剤組成物
US5574159A (en)	1992-02-03	1996-11-12	Delta Pharmaceuticals, Inc.	Opioid compounds and methods for making therefor
US5240929A (en)	1992-08-03	1993-08-31	Warner-Lambert Company	2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5849760A (en)	1993-12-09	1998-12-15	Institut De Recherche Jouveinal	2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
WO1996022997A1 (en)	1995-01-27	1996-08-01	Novo Nordisk A/S	Compounds with growth hormone releasing properties
DE19531464A1 (de)	1995-08-26	1997-02-27	Merck Patent Gmbh	N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
US6518292B1 (en)	1999-03-12	2003-02-11	Bristol-Myers Squibb Co.	Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
DE19924020A1 (de)	1999-05-26	2000-11-30	Basf Ag	Verfahren zur Herstellung von Alkindiolen
US6448323B1 (en)	1999-07-09	2002-09-10	Bpsi Holdings, Inc.	Film coatings and film coating compositions based on polyvinyl alcohol
WO2002024657A2 (en)	2000-09-20	2002-03-28	Schering Corporation	Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CN100400040C (zh)	2000-10-30	2008-07-09	詹森药业有限公司	三肽酶抑制剂
EP1387673B1 (en) *	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Abuse-resistant controlled-release opioid dosage form
BR0213327A (pt)	2001-10-15	2004-10-13	Janssen Pharmaceutica Nv	Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìdos e sua aplicação como agonistas de delta opióides não-peptìdicos seletivos
US7041681B2 (en)	2002-04-29	2006-05-09	Janssen Pharmaceutica N.V.	Compounds as opioid receptor modulators
US20050176746A1 (en)	2002-05-17	2005-08-11	Frank Weber	Use of compounds that are effective as selective opiate receptor modulators
US7201920B2 (en)	2003-11-26	2007-04-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of opioid containing dosage forms
LT2653465T (lt) *	2004-03-15	2016-09-12	Janssen Pharmaceutica Nv	Opioidinio receptoriaus moduliatoriai
WO2007043061A1 (en) *	2005-10-11	2007-04-19	Ipca Laboratories Ltd.	Anti-malarial combination and methods of formulation
WO2008134071A1 (en)	2007-04-26	2008-11-06	Theraquest Biosciences, Inc.	Multimodal abuse resistant extended release formulations
DK2101740T3 (da) *	2006-12-04	2013-11-18	Orexo Ab	Nye ikke-misbrugs-farmaceutiske sammensætninger omfattende opioider
KR101590596B1 (ko)	2007-07-09	2016-02-01	퓨리엑스 파마슈티컬스, 인코포레이티드	신규한 결정 및 5-（｛［2-아미노-3-（4-카르바모일-2,6-다이메틸-페닐）-프로피오닐］-［1-（4-페닐-1ｈ-이미다졸-2-일）-에틸］-아미노｝-메틸）-2-메톡시-벤조산의 제조 방법
AU2008286914B2 (en)	2007-08-13	2014-10-02	Ohemo Life Sciences Inc.	Abuse resistant drugs, method of use and method of making
CN102026628A (zh) *	2008-02-15	2011-04-20	太阳医药高级研发有限公司	具有降低崩裂效果的口服控释片剂
US20090263476A1 (en) *	2008-04-16	2009-10-22	Jobdevairakkam Christopher N	Composition of Rapid Disintegrating Direct Compression Buccal Tablet
EP2448406B1 (en) *	2009-02-26	2016-04-20	Relmada Therapeutics, Inc.	Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US20100285164A1 (en)	2009-05-11	2010-11-11	Jrs Pharma	Orally Disintegrating Excipient
CA2773003A1 (en)	2009-09-15	2011-03-24	Ratiopharm Gmbh	Orally disintegrating pharmaceutical dosage form containing aripiprazole
EP3315124B1 (en)	2009-11-13	2021-01-06	Astrazeneca AB	Bilayer tablet formulations
US9675587B2 (en)	2013-03-14	2017-06-13	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations
MX2019005851A (es)	2016-11-22	2019-10-07	Alkalidx Inc	Terapias para el tratamiento de afecciones hipocalemicas e ineficaces a lidocaina.
WO2018136554A1 (en)	2017-01-17	2018-07-26	Menlo Therapeutics Inc.	Use of neurokinin-1 antagonists as antitussives
WO2018229704A1 (en)	2017-06-15	2018-12-20	Laurus Labs Limited	Novel polymorphs of eluxadoline and its solvates, process for its preparation and pharmaceutical composition thereof
US12285411B2 (en)	2019-09-10	2025-04-29	Aurobindo Pharma Ltd	Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof
US20220016034A1 (en)	2020-07-17	2022-01-20	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations

2013
- 2013-03-14 US US13/829,984 patent/US9675587B2/en active Active
2014
- 2014-02-26 TW TW103106575A patent/TWI648071B/zh not_active IP Right Cessation
- 2014-03-10 HU HUE14774006A patent/HUE042748T2/hu unknown
- 2014-03-10 EA EA201591768A patent/EA031559B1/ru not_active IP Right Cessation
- 2014-03-10 DK DK14774006.2T patent/DK2968351T3/en active
- 2014-03-10 SI SI201430934T patent/SI2968351T1/sl unknown
- 2014-03-10 TR TR2018/15953T patent/TR201815953T4/tr unknown
- 2014-03-10 WO PCT/US2014/022666 patent/WO2014159245A1/en not_active Ceased
- 2014-03-10 CA CA3254178A patent/CA3254178A1/en active Pending
- 2014-03-10 ES ES14774006.2T patent/ES2693374T3/es active Active
- 2014-03-10 EP EP14774006.2A patent/EP2968351B1/en active Active
- 2014-03-10 PT PT14774006T patent/PT2968351T/pt unknown
- 2014-03-10 CA CA2906472A patent/CA2906472A1/en active Pending
- 2014-03-10 KR KR1020157028735A patent/KR102435440B1/ko active Active
- 2014-03-10 AU AU2014241076A patent/AU2014241076B2/en not_active Ceased
- 2014-03-10 EP EP20215626.1A patent/EP3865131A1/en not_active Withdrawn
- 2014-03-10 EP EP18187598.0A patent/EP3456321A1/en not_active Withdrawn
- 2014-03-10 JP JP2016501031A patent/JP6449225B2/ja not_active Expired - Fee Related
- 2014-03-10 CN CN201911036853.XA patent/CN110917159A/zh active Pending
- 2014-03-10 BR BR112015022753A patent/BR112015022753A8/pt not_active Application Discontinuation
- 2014-03-10 PL PL14774006T patent/PL2968351T3/pl unknown
- 2014-03-10 CN CN201480026522.7A patent/CN105228629A/zh active Pending
2015
- 2015-09-10 IL IL241561A patent/IL241561B/en active IP Right Grant
2017
- 2017-05-05 US US15/588,304 patent/US10188632B2/en active Active
2018
- 2018-10-05 JP JP2018189781A patent/JP6666975B2/ja not_active Expired - Fee Related
- 2018-11-23 CY CY181101243T patent/CY1120892T1/el unknown
2019
- 2019-08-15 IL IL268718A patent/IL268718B/en active IP Right Grant
2020
- 2020-10-08 US US17/066,072 patent/US11007179B2/en active Active
2021
- 2021-02-12 US US17/175,082 patent/US11090291B2/en active Active
- 2021-03-24 US US17/211,274 patent/US11160792B2/en active Active
- 2021-09-22 US US17/481,874 patent/US11311516B2/en active Active
- 2021-10-21 US US17/507,091 patent/US11229627B1/en active Active
- 2021-12-08 US US17/545,584 patent/US11484527B2/en active Active
2023
- 2023-05-26 US US18/324,449 patent/US12097187B2/en active Active

Also Published As

Publication number	Publication date
US11090291B2 (en)	2021-08-17
US10188632B2 (en)	2019-01-29
JP2019014744A (ja)	2019-01-31
US12097187B2 (en)	2024-09-24
US11229627B1 (en)	2022-01-25
CA2906472A1 (en)	2014-10-02
US20170304268A1 (en)	2017-10-26
SI2968351T1 (sl)	2019-01-31
IL241561B (en)	2019-09-26
CN110917159A (zh)	2020-03-27
ES2693374T3 (es)	2018-12-11
AU2014241076B2 (en)	2018-07-19
US11311516B2 (en)	2022-04-26
HK1218514A1 (en)	2017-02-24
EP2968351A4 (en)	2016-08-24
CA3254178A1 (en)	2025-05-13
US20220040151A1 (en)	2022-02-10
IL268718B (en)	2021-04-29
EP2968351A1 (en)	2016-01-20
KR102435440B1 (ko)	2022-08-22
US20220008394A1 (en)	2022-01-13
US20210030720A1 (en)	2021-02-04
EA201591768A1 (ru)	2016-03-31
EA031559B1 (ru)	2019-01-31
BR112015022753A2 (pt)	2017-07-18
EP3865131A1 (en)	2021-08-18
US20230293493A1 (en)	2023-09-21
EP2968351B1 (en)	2018-08-29
IL268718A (en)	2019-10-31
PL2968351T3 (pl)	2019-03-29
TR201815953T4 (tr)	2018-11-21
CN105228629A (zh)	2016-01-06
KR20150140681A (ko)	2015-12-16
US20210205269A1 (en)	2021-07-08
DK2968351T3 (en)	2018-11-26
JP6449225B2 (ja)	2019-01-09
EP3456321A1 (en)	2019-03-20
BR112015022753A8 (pt)	2019-11-26
JP6666975B2 (ja)	2020-03-18
US9675587B2 (en)	2017-06-13
HUE042748T2 (hu)	2019-07-29
WO2014159245A1 (en)	2014-10-02
US20140271854A1 (en)	2014-09-18
CY1120892T1 (el)	2019-12-11
US11484527B2 (en)	2022-11-01
US11160792B2 (en)	2021-11-02
AU2014241076A1 (en)	2015-10-01
JP2016516694A (ja)	2016-06-09
US20210205268A1 (en)	2021-07-08
US20220096440A1 (en)	2022-03-31
US11007179B2 (en)	2021-05-18
TW201444590A (zh)	2014-12-01
TWI648071B (zh)	2019-01-21

Publication	Publication Date	Title
DK3848027T3 (da)	2023-05-01	Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
EP2972351A4 (en)	2016-08-24	IMPROVED TEST PROCEDURES
DK3030262T3 (da)	2019-12-02	Kombineret farmaceutisk sammensætning
PL2919766T3 (pl)	2021-10-04	Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
DK2890434T3 (da)	2020-07-20	Lægemiddeladministrationsanordning
GB201322602D0 (en)	2014-02-05	Pharmaceutical compounds
PT3089754T (pt)	2021-07-23	Formulações de vacina de dose única
DK2970389T3 (da)	2020-10-26	Farmaceutiske forbindelser
GB201306610D0 (en)	2013-05-29	Pharmaceutical compounds
EP2953618A4 (en)	2016-11-30	MANIPULATION-SAFE PHARMACEUTICAL FORMULATIONS
DK3287133T3 (da)	2019-07-01	Proton-bindende polymerer til oral indgivelse
IL268718B (en)	2021-04-29	Opioid receptor modulator dosage formulations
IL244380A0 (en)	2016-04-21	Pharmaceutical compounds
BR112016014512A2 (pt)	2018-05-22	formulações farmacêuticas líquidas de pemetrexede
SG11201509194SA (en)	2015-12-30	Radiomitigating pharmaceutical formulations
IL245705B (en)	2021-05-31	Pharmaceutical dosage forms
DK3003401T3 (da)	2020-04-06	Farmaceutisk præparat
GB201312386D0 (en)	2013-08-21	Pharmaceutical compounds
EP3043648C0 (en)	2023-09-20	PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE
EP2964257A4 (en)	2016-10-26	RECIPE FOR TRANSCUTANEOUS DOSING
GB201317166D0 (en)	2013-11-06	Pharmaceutical compounds
BR112014021433A2 (pt)	2017-07-18	formulações farmacêuticas
DK3071261T3 (da)	2019-07-29	Lægemiddeladministrationsanordning
DK2890435T3 (da)	2020-05-25	Lægemiddeladministrationsanordning
ES1084079Y (es)	2013-10-01	Dosificador de Pastillas